Determination of a radotinib dosage regimen based on dose-response relationships for the treatment of newly diagnosed patients with chronic myeloid leukemia-Reference-Cited by-同舟云学术

Determination of a radotinib dosage regimen based on dose-response relationships for the treatment of newly diagnosed patients with chronic myeloid leukemia

Published:2018-03-25 Issue:5 Volume:7 Page:1766-1773
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Noh Hayeon¹,Jung Su Young²³,Kwak Jae-Yong⁴,Kim Sung-Hyun⁵,Oh Suk Joong⁶,Zang Dae Young⁷,Lee Suhyun²³,Park Hye Lin⁸,Jo Dae Jin⁸,Shin Jae Soo⁸,Do Young Rok⁹,Kim Dong-Wook¹⁰,Lee Jangik I.²³^ORCID

Affiliation:

1. Department of Pharmacy; College of Pharmacy; Yonsei University; Incheon Korea

2. Department of Pharmacy; College of Pharmacy; Seoul National University; Seoul Korea

3. Research Institute of Pharmaceutical Sciences; Seoul National University; Seoul Korea

4. Chonbuk National University Medical School & Hospital; Jeonju Korea

5. Department of Internal Medicine; Dong-A University College of Medicine; Busan Korea

6. Department of Internal Medicine; Kangbuk Samsung Hospital; Sungkyunkwan University School of Medicine; Seoul Korea

7. Department of Internal Medicine; Hallym University Sacred Heart Hospital; Anyang Korea

8. Central Research Institute; IL-YANG Pharmaceutical Co., Ltd.; Yongin Korea

9. Department of Medicine; Dongsan Medical Center; Keimyung University; Daegu Korea

10. Seoul St. Mary's Hospital; Leukemia Research Institute; The Catholic University of Korea; Seoul Korea

Funder

IL-YANG Pharmaceutical Co., Ltd.

Seoul National University

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Reference32 articles.

1. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias;Talpaz;N. Engl. J. Med.,2006

2. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia;O'Brien;N. Engl. J. Med.,2003

3. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL;Kantarjian;N. Engl. J. Med.,2006

4. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study;Larson;Blood,2008

5. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia;Picard;Blood,2007

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Research Status, Synthesis and Clinical Application of Recently Marketed and Clinical BCR-ABL Inhibitors;Current Medicinal Chemistry;2021-10-12

2. Appropriate Starting Dose of Dasatinib Based on Analyses of Dose-Limiting Toxicities and Molecular Responses in Asian Patients With Chronic Myeloid Leukemia;Clinical Lymphoma Myeloma and Leukemia;2021-06

3. Development of a dried blood spot sampling method towards therapeutic monitoring of radotinib in the treatment of chronic myeloid leukaemia;Journal of Clinical Pharmacy and Therapeutics;2020-02-05

4. Comprehensive analyses of safety and efficacy toward individualizing imatinib dosage in patients with chronic myeloid leukemia;International Journal of Hematology;2019-12-20